Ascendis Pharma A/S (ASND)
| Market Cap | 7.00B |
| Revenue (ttm) | 4.02M |
| Net Income (ttm) | -489.98M |
| Shares Out | 56.94M |
| EPS (ttm) | -8.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 246,404 |
| Open | 119.05 |
| Previous Close | 119.05 |
| Day's Range | 116.79 - 128.49 |
| 52-Week Range | 109.36 - 178.71 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 193.52 (+57.4%) |
| Earnings Date | Nov 10, 2021 |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo...
Analyst Forecast
According to 12 analysts, the average rating for ASND stock is "Buy." The 12-month stock price forecast is 193.52, which is an increase of 57.39% from the latest price.
News
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a onc...
Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency
TransCon hGH (approved by the European Commission as Lonapegsomatropin Ascendis Pharma) is a once-weekly prodrug of somatropin for pediatric patients diagnosed with growth hormone deficiency TransCon hG...
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday,...
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP). Hypoparathyroidism is a condition in w...
Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that Tran...
–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.
Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conferenc...
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Defic...
– TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency.
Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
– SKYTROFA ® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021.
Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10
COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 a...
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Ap...
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for ...
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mi...
– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company's Phase 2 PaTH Forward Trial –
Ascendis Pharma A/S Announces Share Repurchase Program
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Cont...
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Ascendis Pharma A/S Announces Upcoming Investor Presentations
COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program
– TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation ...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treat...
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
Why Shares of Ascendis Soared This Week
The pharmaceutical company saw its shares jump more than $26.
Here's Why Ascendis Pharma Shares Are Surging Higher Today
Approval of the company's weekly growth hormone is making investors smile today.
See Why Ascendis Pharma Stock Is Shining On Thursday
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ag...